Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Sci

Retrieve available abstracts of 194 articles:
HTML format
Text format



Single Articles


    July 2018
  1. VOLLMER B, Honce JM, Sillau S, Corboy JR, et al
    The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
    J Neurol Sci. 2018;390:89-93.
    PubMed     Text format     Abstract available


  2. ZHANG Y, Wang L, Jia H, Liao M, et al
    Genetic variants regulate NR1H3 expression and contribute to multiple sclerosis risk.
    J Neurol Sci. 2018;390:162-165.
    PubMed     Text format     Abstract available


    May 2018
  3. KADRNOZKOVA L, Vaneckova M, Sobisek L, Benova B, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.
    J Neurol Sci. 2018;388:87-93.
    PubMed     Text format     Abstract available


  4. GROMISCH ES, Portnoy JG, Foley FW
    Comparison of the abbreviated minimal assessment of cognitive function in multiple sclerosis (aMACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS).
    J Neurol Sci. 2018;388:70-75.
    PubMed     Text format     Abstract available


  5. ZIVADINOV R, Bergsland N, Hagemeier J, Carl E, et al
    Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
    J Neurol Sci. 2018;388:175-181.
    PubMed     Text format     Abstract available


  6. KANTOR D, Johnson K, Vieira MC, Signorovitch J, et al
    Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2018;388:168-174.
    PubMed     Text format     Abstract available


  7. FABIS-PEDRINI MJ, James I, Seewann A, Yau WY, et al
    Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.
    J Neurol Sci. 2018;388:12-18.
    PubMed     Text format     Abstract available


  8. MANCA R, Sharrack B, Paling D, Wilkinson ID, et al
    Brain connectivity and cognitive processing speed in multiple sclerosis: A systematic review.
    J Neurol Sci. 2018;388:115-127.
    PubMed     Text format     Abstract available


    April 2018
  9. DALGAS U, Langeskov-Christensen M, Skjerbaek A, Jensen E, et al
    Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study.
    J Neurol Sci. 2018;387:179-186.
    PubMed     Text format     Abstract available


  10. VYVER MV, Beelen R, De Keyser J, Nagels G, et al
    Plasma citrulline levels are increased in patients with multiple sclerosis.
    J Neurol Sci. 2018;387:174-178.
    PubMed     Text format     Abstract available


  11. ZIVADINOV R, Bergsland N, Hagemeier J, Tavazzi E, et al
    Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    J Neurol Sci. 2018;387:152-156.
    PubMed     Text format     Abstract available


  12. AKAISHI T, Takahashi T, Nakashima I
    Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability.
    J Neurol Sci. 2018;387:129-133.
    PubMed     Text format     Abstract available


  13. GRIST JT, Riemer F, McLean MA, Matys T, et al
    Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from (23)Na-MRI.
    J Neurol Sci. 2018;387:111-114.
    PubMed     Text format     Abstract available


    March 2018
  14. FENU G, Lorefice L, Arru M, Sechi V, et al
    Cognition in multiple sclerosis: Between cognitive reserve and brain volume.
    J Neurol Sci. 2018;386:19-22.
    PubMed     Text format     Abstract available


    February 2018
  15. MORROW SA, Rosehart H, Sener A, Welk B, et al
    Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis.
    J Neurol Sci. 2018;385:39-44.
    PubMed     Text format     Abstract available


  16. BUNAI T, Terada T, Kono S, Yokokura M, et al
    Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study.
    J Neurol Sci. 2018;385:30-33.
    PubMed     Text format     Abstract available


  17. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2018;385:217-224.
    PubMed     Text format     Abstract available


  18. PODBIELSKA M, O'Keeffe J, Hogan EL
    Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration.
    J Neurol Sci. 2018;385:198-214.
    PubMed     Text format     Abstract available


  19. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224].
    J Neurol Sci. 2018 Feb 12. pii: S0022-510X(18)30061.
    PubMed     Text format    


    December 2017
  20. DALLA-COSTA G, Radaelli M, Maida S, Sangalli F, et al
    Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice.
    J Neurol Sci. 2017;383:166-168.
    PubMed     Text format     Abstract available


  21. LINGENBERG A, Laidet M, Armand S, Herrmann FR, et al
    Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.
    J Neurol Sci. 2017;383:105-107.
    PubMed     Text format    


    November 2017
  22. PEREZ-MARTIN MY, Gonzalez-Platas M, Jimenez-Sosa A, Plata-Bello J, et al
    Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?
    J Neurol Sci. 2017;382:66-72.
    PubMed     Text format     Abstract available


  23. PLANCHE V, Moisset X, Morello R, Dumont E, et al
    Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    J Neurol Sci. 2017;382:148-154.
    PubMed     Text format     Abstract available


  24. LANGESKOV-CHRISTENSEN D, Feys P, Baert I, Riemenschneider M, et al
    Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.
    J Neurol Sci. 2017;382:131-136.
    PubMed     Text format     Abstract available


    October 2017
  25. YOUSUF F, Dupuy SL, Tauhid S, Chu R, et al
    A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    J Neurol Sci. 2017 Oct 16. pii: S0022-510X(17)34384.
    PubMed     Text format     Abstract available


  26. MILLER P, Soundy A
    The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis.
    J Neurol Sci. 2017;381:41-54.
    PubMed     Text format     Abstract available


  27. KARAMI M, Mehrabi F, Allameh A, Pahlevan Kakhki M, et al
    Klotho gene expression decreases in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2017;381:305-307.
    PubMed     Text format     Abstract available


  28. FERREIRA D, Castro P, Videira G, Filipe JP, et al
    Cerebral autoregulation is preserved in multiple sclerosis patients.
    J Neurol Sci. 2017;381:298-304.
    PubMed     Text format     Abstract available


  29. CALVI A, De Riz M, Lecchi E, Pietroboni A, et al
    Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    J Neurol Sci. 2017;381:296-297.
    PubMed     Text format    


  30. OLIVEIRA SR, Simao ANC, Alfieri DF, Flauzino T, et al
    Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
    J Neurol Sci. 2017;381:213-219.
    PubMed     Text format     Abstract available


  31. CORREALE J
    Follow-on products for treatment of multiple sclerosis in Latin America: An update.
    J Neurol Sci. 2017;381:153-159.
    PubMed     Text format     Abstract available


  32. BEIER M, Gromisch ES, Hughes AJ, Alschuler KN, et al
    Proposed cut scores for tests of the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS).
    J Neurol Sci. 2017;381:110-116.
    PubMed     Text format     Abstract available


  33. MCGEE JC, Minagar A
    Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
    J Neurol Sci. 2017 Oct 13. pii: S0022-510X(17)34383.
    PubMed     Text format    


    September 2017
  34. YAMOUT BI, Said M, Hannoun S, Zeineddine M, et al
    Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    J Neurol Sci. 2017;380:79-81.
    PubMed     Text format     Abstract available


  35. YANG TT, Wang L, Deng XY, Yu G, et al
    Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;380:256-261.
    PubMed     Text format     Abstract available


  36. GREEKE EE, Chua AS, Healy BC, Rintell DJ, et al
    Depression and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;380:236-241.
    PubMed     Text format     Abstract available


  37. IWANOWSKI P, Losy J, Kramer L, Wojcicka M, et al
    CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    J Neurol Sci. 2017;380:22-26.
    PubMed     Text format     Abstract available


  38. LAIDET M, Herrmann FR, Armand S, Assal F, et al
    Does fear of falling predict gait variability in multiple sclerosis?
    J Neurol Sci. 2017;380:212-214.
    PubMed     Text format     Abstract available


  39. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].
    J Neurol Sci. 2017;380:19.
    PubMed     Text format    


  40. PICELLI A, Vallies G, Chemello E, Castellazzi P, et al
    Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis.
    J Neurol Sci. 2017;380:132-136.
    PubMed     Text format     Abstract available


    August 2017
  41. SANTORO M, Mirabella M, De Fino C, Bianco A, et al
    Sativex(R) effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
    J Neurol Sci. 2017;379:298-303.
    PubMed     Text format     Abstract available


  42. GAETANI L, Fanelli F, Riccucci I, Eusebi P, et al
    High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.
    J Neurol Sci. 2017;379:236-240.
    PubMed     Text format     Abstract available


  43. KEUNE PM, Young WR, Paraskevopoulos IT, Hansen S, et al
    Measuring standing balance in multiple sclerosis: Further progress towards an automatic and reliable method in clinical practice.
    J Neurol Sci. 2017;379:157-162.
    PubMed     Text format     Abstract available


  44. MORSALJAHAN Z, Rafiei A, Valadan R, Abedini M, et al
    Association between interleukin-32 polymorphism and multiple sclerosis.
    J Neurol Sci. 2017;379:144-150.
    PubMed     Text format     Abstract available


    July 2017
  45. FARROKHI M, Masoudifar A, Peykanpour F
    Interleukin 17 and 10 in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017;378:63.
    PubMed     Text format    


  46. ROLF L, Muris AH, Bol Y, Damoiseaux J, et al
    Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression.
    J Neurol Sci. 2017;378:30-35.
    PubMed     Text format     Abstract available


  47. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    J Neurol Sci. 2017;378:233-237.
    PubMed     Text format     Abstract available


  48. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Concerning the article "Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients".
    J Neurol Sci. 2017;378:152.
    PubMed     Text format    


    June 2017
  49. AGLIARDI C, Guerini FR, Zanzottera M, Rovaris M, et al
    Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.
    J Neurol Sci. 2017;377:31-34.
    PubMed     Text format     Abstract available


  50. CALABRO RS, Russo M, Naro A, De Luca R, et al
    Robotic gait training in multiple sclerosis rehabilitation: Can virtual reality make the difference? Findings from a randomized controlled trial.
    J Neurol Sci. 2017;377:25-30.
    PubMed     Text format     Abstract available


  51. TRENTINI A, Castellazzi M, Romani A, Squerzanti M, et al
    Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    J Neurol Sci. 2017;377:133-136.
    PubMed     Text format     Abstract available


  52. SMOLDERS J, Rolf L, Damoiseaux J, Hupperts R, et al
    On the ethics of not supplementing low 25-hydroxyvitamin D levels in a controlled study in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30383.
    PubMed     Text format    


  53. SHUKLA L, Solanki C, Kulkarni Y, Vadlamani N, et al
    Vitamin D supplementation; effects on depressive symptoms in multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30384.
    PubMed     Text format    


    May 2017
  54. JORGENSEN M, Dalgas U, Wens I, Hvid LG, et al
    Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis.
    J Neurol Sci. 2017;376:225-241.
    PubMed     Text format     Abstract available


  55. HEESEN C, Kleiter I, Meuth SG, Kramer J, et al
    Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    J Neurol Sci. 2017;376:181-190.
    PubMed     Text format     Abstract available


  56. BSTEH G, Monz E, Zamarian L, Hagspiel S, et al
    Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice - The PeRiCoMS-Study I.
    J Neurol Sci. 2017;376:71-75.
    PubMed     Text format     Abstract available


  57. WEINSTOCK-GUTTMAN B, Nair KV, Glajch JL, Ganguly TC, et al
    Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    J Neurol Sci. 2017;376:255-259.
    PubMed     Text format     Abstract available


    April 2017
  58. BOURNE T, Waltz M, Casper TC, Kavak K, et al
    Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.
    J Neurol Sci. 2017;375:371-375.
    PubMed     Text format     Abstract available


  59. LYSANDROPOULOS AP, Mavroudakis N, Pandolfo M, El Hafsi K, et al
    HLA genotype as a marker of multiple sclerosis prognosis: A pilot study.
    J Neurol Sci. 2017;375:348-354.
    PubMed     Text format     Abstract available


  60. NOORI-ZADEH A, Mesbah-Namin SA, Saboor-Yaraghi AA
    Epigenetic and gene expression alterations of FOXP3 in the T cells of EAE mouse model of multiple sclerosis.
    J Neurol Sci. 2017;375:203-208.
    PubMed     Text format     Abstract available


  61. RUBEGNI A, Battisti C, Tessa A, Cerase A, et al
    SPG2 mimicking multiple sclerosis in a family identified using next generation sequencing.
    J Neurol Sci. 2017;375:198-202.
    PubMed     Text format     Abstract available


  62. HARTL C, Obermeier V, Gerdes LA, Brugel M, et al
    Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.
    J Neurol Sci. 2017;375:160-164.
    PubMed     Text format     Abstract available


  63. REEN GK, Silber E, Langdon DW
    Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review.
    J Neurol Sci. 2017;375:107-122.
    PubMed     Text format     Abstract available


    February 2017
  64. ZHOU Y, Fang L, Peng L, Qiu W, et al
    TLR9 and its signaling pathway in multiple sclerosis.
    J Neurol Sci. 2017;373:95-99.
    PubMed     Text format     Abstract available


  65. WUNDES A, Bowen JD, Kraft GH, Maravilla KR, et al
    Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Sci. 2017;373:339-341.
    PubMed     Text format     Abstract available


  66. LANGESKOV-CHRISTENSEN M, Bisson EJ, Finlayson ML, Dalgas U, et al
    Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review.
    J Neurol Sci. 2017;373:307-320.
    PubMed     Text format     Abstract available


  67. FERREIRA KP, Oliveira SR, Kallaur AP, Kaimen-Maciel DR, et al
    Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:236-241.
    PubMed     Text format     Abstract available


  68. KAWADA T
    Poor sleep and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:143.
    PubMed     Text format    


  69. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study" by Tomoyuki Kawada.
    J Neurol Sci. 2017;373:142.
    PubMed     Text format    


  70. ZAHOOR I, Haq E, Asimi R
    Multiple sclerosis in Kashmir: Where we stand.
    J Neurol Sci. 2017;373:129-133.
    PubMed     Text format     Abstract available


  71. TOGHI M, Taheri M, Arsang-Jang S, Ohadi M, et al
    SOCS gene family expression profile in the blood of multiple sclerosis patients.
    J Neurol Sci. 2017 Feb 9. pii: S0022-510X(17)30111.
    PubMed     Text format     Abstract available


    January 2017
  72. ALGAHTANI H, Marzouk Y, Algahtani R, Salman S, et al
    Autosomal Recessive Cerebellar Ataxia type 1 mimicking multiple sclerosis: A report of two siblings with a novel mutation in SYNE1 gene in a Saudi family.
    J Neurol Sci. 2017;372:97-100.
    PubMed     Text format     Abstract available


  73. MOTL RW, Sandroff BM, Pilutti LA, Klaren RE, et al
    Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis.
    J Neurol Sci. 2017;372:342-346.
    PubMed     Text format     Abstract available


  74. BOESCHOTEN RE, Braamse AM, Beekman AT, Cuijpers P, et al
    Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;372:331-341.
    PubMed     Text format     Abstract available


  75. CAMEROTA F, Celletti C, Di Sipio E, De Fino C, et al
    Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis.
    J Neurol Sci. 2017;372:33-39.
    PubMed     Text format     Abstract available


  76. SABATINO JJ JR, Newsome SD
    Stiff person syndrome masquerading as multiple sclerosis.
    J Neurol Sci. 2017;372:297-299.
    PubMed     Text format     Abstract available


  77. CRNOSIJA L, Krbot Skoric M, Gabelic T, Adamec I, et al
    Vestibular evoked myogenic potentials and MRI in early multiple sclerosis: Validation of the VEMP score.
    J Neurol Sci. 2017;372:28-32.
    PubMed     Text format     Abstract available


  78. KISIC-TEPAVCEVIC D, Pekmezovic T, Trajkovic G, Stojsavljevic N, et al
    Corrigendum to "Sexual dysfunction in multiple sclerosis: A 6-year follow-up study" [J. Neurol. Sci. 358 (2015) 317-323].
    J Neurol Sci. 2017;372:201.
    PubMed     Text format    


  79. CHALAH MA, Riachi N, Ahdab R, Mhalla A, et al
    Effects of left DLPFC versus right PPC tDCS on multiple sclerosis fatigue.
    J Neurol Sci. 2017;372:131-137.
    PubMed     Text format     Abstract available


  80. TAO C, Simpson S Jr, Taylor BV, van der Mei I, et al
    Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.
    J Neurol Sci. 2017;372:239-249.
    PubMed     Text format     Abstract available


  81. BEH SC, Kildebeck E, Narayan R, Desena A, et al
    High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
    J Neurol Sci. 2017;372:187-195.
    PubMed     Text format     Abstract available


  82. TANIKAWA M, Nakahara J, Hata J, Suzuki S, et al
    q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
    J Neurol Sci. 2017 Jan 5. pii: S0022-510X(17)30010.
    PubMed     Text format     Abstract available


  83. KIRA JI
    q-space Myelin Map imaging: A new imaging technique for treatment evaluation in multiple sclerosis.
    J Neurol Sci. 2017 Jan 4. pii: S0022-510X(17)30009.
    PubMed     Text format    


    December 2016
  84. KOUDRIAVTSEVA T
    Body mass index and interferon-beta efficacy (and safety) in multiple sclerosis.
    J Neurol Sci. 2016;371:79-80.
    PubMed     Text format    


    November 2016
  85. HERNANDEZ ME, Holtzer R, Chaparro G, Jean K, et al
    Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
    J Neurol Sci. 2016;370:277-283.
    PubMed     Text format     Abstract available


  86. SQUINTANI G, Donato F, Turri M, Deotto L, et al
    Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    J Neurol Sci. 2016;370:263-268.
    PubMed     Text format     Abstract available


  87. O'GORMAN CM, Broadley SA
    Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia.
    J Neurol Sci. 2016;370:219-223.
    PubMed     Text format     Abstract available


  88. DE GIGLIO L, Upadhyay N, De Luca F, Prosperini L, et al
    Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.
    J Neurol Sci. 2016;370:211-213.
    PubMed     Text format    


  89. GAINDH D, Kavak KS, Teter B, Vaughn CB, et al
    Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    J Neurol Sci. 2016;370:13-17.
    PubMed     Text format     Abstract available


  90. GASPERINI C, Hupperts R, Lycke J, Short C, et al
    Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    J Neurol Sci. 2016;370:123-131.
    PubMed     Text format     Abstract available


  91. HUHN K, Lammer R, Zimmermann H, Lammer A, et al
    Retinal imaging and axonal degeneration in later onset multiple sclerosis.
    J Neurol Sci. 2016;370:1-6.
    PubMed     Text format     Abstract available


    October 2016
  92. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study.
    J Neurol Sci. 2016 Oct 27. pii: S0022-510X(16)30684.
    PubMed     Text format     Abstract available


  93. EFTEKHARIAN MM, Noroozi R, Sayad A, Sarrafzadeh S, et al
    RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis.
    J Neurol Sci. 2016;369:259-62.
    PubMed     Text format     Abstract available


  94. BERNARDINI LR, Zecca C, Clerici VT, Gobbi C, et al
    Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
    J Neurol Sci. 2016;369:139-40.
    PubMed     Text format    


  95. YANG F, Estrada EF, Sanchez MC
    Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study.
    J Neurol Sci. 2016;369:96-101.
    PubMed     Text format     Abstract available


  96. MANDEL JJ, Goethe EA, Patel AJ, Heck K, et al
    Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis.
    J Neurol Sci. 2016;369:51-2.
    PubMed     Text format    


  97. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2016;369:36-8.
    PubMed     Text format     Abstract available


    September 2016
  98. STELLMANN JP, Jlussi M, Neuhaus A, Lederer C, et al
    Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    J Neurol Sci. 2016;368:318-25.
    PubMed     Text format     Abstract available


  99. BENITO-LEON J, Domingo-Santos A
    Gut microflora and multiple sclerosis.
    J Neurol Sci. 2016;368:254.
    PubMed     Text format    


  100. BRAMBILLA L, Rossi Sebastiano D, Aquino D, Torri Clerici V, et al
    Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    J Neurol Sci. 2016;368:402-7.
    PubMed     Text format     Abstract available


  101. MESSMER UCCELLI M, Traversa S, Ponzio M
    A survey study comparing young adults with MS and healthy controls on self-esteem, self-efficacy, mood and quality of life.
    J Neurol Sci. 2016;368:369-73.
    PubMed     Text format     Abstract available


  102. SACCA F, Pane C, Carotenuto A, Massarelli M, et al
    The use of medical-grade cannabis in patients non-responders to Nabiximols.
    J Neurol Sci. 2016;368:349-51.
    PubMed     Text format    


    August 2016
  103. MASUDA H, Mori M, Uzawa A, Muto M, et al
    Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol Sci. 2016;367:375-9.
    PubMed     Text format     Abstract available


  104. SANDI D, Zsiros V, Fuvesi J, Kincses ZT, et al
    Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013.
    J Neurol Sci. 2016;367:329-32.
    PubMed     Text format     Abstract available


  105. CHRUZANDER C, Tinghog P, Ytterberg C, Widen Holmqvist L, et al
    Longitudinal changes in sickness absence and disability pension, and associations between disability pension and disease-specific and contextual factors and functioning, in people with multiple sclerosis.
    J Neurol Sci. 2016;367:319-25.
    PubMed     Text format     Abstract available


  106. MANTERO V, Borelli P, Rigamonti A, Fiumani A, et al
    Autoimmunity meets genetics: Multiple sclerosis in a patient with Kallmann syndrome.
    J Neurol Sci. 2016;367:256-7.
    PubMed     Text format    


  107. ABDOLLAHZADEH R, Fard MS, Rahmani F, Moloudi K, et al
    Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: A case-control study.
    J Neurol Sci. 2016;367:148-51.
    PubMed     Text format     Abstract available


  108. VIDEIRA G, Castro P, Vieira B, Filipe JP, et al
    Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage.
    J Neurol Sci. 2016;367:133-7.
    PubMed     Text format     Abstract available


  109. WENS I, Eijnde BO, Hansen D
    Muscular, cardiac, ventilatory and metabolic dysfunction in patients with multiple sclerosis: Implications for screening, clinical care and endurance and resistance exercise therapy, a scoping review.
    J Neurol Sci. 2016;367:107-21.
    PubMed     Text format     Abstract available


    July 2016
  110. NOURBAKHSH B, Azevedo C, Maghzi AH, Spain R, et al
    Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
    J Neurol Sci. 2016;366:229-33.
    PubMed     Text format     Abstract available


  111. GIORDANO A, Cimino V, Campanella A, Morone G, et al
    Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis.
    J Neurol Sci. 2016;366:139-45.
    PubMed     Text format    


    June 2016
  112. HUNTER SF, Agius M, Miller DM, Cutter G, et al
    Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
    J Neurol Sci. 2016;365:190-8.
    PubMed     Text format     Abstract available


  113. IODICE R, Carotenuto A, Dubbioso R, Cerillo I, et al
    Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
    J Neurol Sci. 2016;365:143-6.
    PubMed     Text format     Abstract available


  114. LANGESKOV-CHRISTENSEN M, Kjolhede T, Stenager E, Jensen HB, et al
    Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?
    J Neurol Sci. 2016;365:114-20.
    PubMed     Text format     Abstract available


  115. LI LM, Yang LN, Zhang LJ, Fu Y, et al
    Olfactory dysfunction in patients with multiple sclerosis.
    J Neurol Sci. 2016;365:34-9.
    PubMed     Text format     Abstract available


  116. ALADRO Y, Terrero R, Cerezo M, Ginestal R, et al
    Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain.
    J Neurol Sci. 2016;365:16-21.
    PubMed     Text format     Abstract available


  117. KUUSISTO H, Vahvelainen T, Hamalainen P, Luukkaala T, et al
    Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.
    J Neurol Sci. 2016;365:50-3.
    PubMed     Text format     Abstract available


    May 2016
  118. PROSPERINI L, Fanelli F, Pozzilli C
    Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
    J Neurol Sci. 2016;364:145-7.
    PubMed     Text format     Abstract available


  119. MONTANARI E, Rottoli M, Maimone D, Confalonieri P, et al
    A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.
    J Neurol Sci. 2016;364:105-9.
    PubMed     Text format     Abstract available


  120. STICH O, Perera S, Berger B, Jarius S, et al
    Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis.
    J Neurol Sci. 2016;364:29-32.
    PubMed     Text format     Abstract available


    April 2016
  121. BECKER J, Callegaro D, Lana-Peixoto MA, Talim N, et al
    Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil.
    J Neurol Sci. 2016;363:236-9.
    PubMed     Text format     Abstract available


  122. HUBBARD EA, Wetter NC, Sutton BP, Pilutti LA, et al
    Diffusion tensor imaging of the corticospinal tract and walking performance in multiple sclerosis.
    J Neurol Sci. 2016;363:225-31.
    PubMed     Text format     Abstract available


  123. FOX EJ, Wynn D, Coles AJ, Palmer J, et al
    Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
    J Neurol Sci. 2016;363:188-94.
    PubMed     Text format     Abstract available


  124. KASSI E, Semaniakou A, Sertedaki A, Evangelopoulos ME, et al
    Sequencing analysis of the human glucocorticoid receptor (NR3C1) gene in multiple sclerosis patients.
    J Neurol Sci. 2016;363:165-9.
    PubMed     Text format     Abstract available


  125. BOSNJAK PASIC M, Hajnsek S, Panajatovic M, Vidrih B, et al
    Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
    J Neurol Sci. 2016;363:145-6.
    PubMed     Text format    


  126. ZHANG Z, Wang L, Sun X, Zhang L, et al
    Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: A meta-analysis.
    J Neurol Sci. 2016;363:107-13.
    PubMed     Text format     Abstract available


  127. PEYRO SAINT PAUL L, Creveuil C, Heinzlef O, De Seze J, et al
    Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    J Neurol Sci. 2016;363:69-76.
    PubMed     Text format     Abstract available


  128. KRUPP LB, Pohl D, Ghezzi A, Boyko A, et al
    Subcutaneous interferon beta-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study.
    J Neurol Sci. 2016;363:33-8.
    PubMed     Text format     Abstract available


  129. ZIVKOVIC M, Kolakovic A, Stojkovic L, Dincic E, et al
    Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis.
    J Neurol Sci. 2016;363:29-32.
    PubMed     Text format     Abstract available


  130. TREMLETT H, Fadrosh DW, Faruqi AA, Hart J, et al
    Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
    J Neurol Sci. 2016;363:153-7.
    PubMed     Text format     Abstract available


    March 2016
  131. KIERKEGAARD M, Lundberg IE, Olsson T, Johansson S, et al
    High-intensity resistance training in multiple sclerosis - An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition.
    J Neurol Sci. 2016;362:251-7.
    PubMed     Text format     Abstract available


  132. THONE J, Kleiter I, Stahl A, Ellrichmann G, et al
    Relevance of endoglin, IL-1alpha, IL-1beta and anti-ovarian antibodies in females with multiple sclerosis.
    J Neurol Sci. 2016;362:240-3.
    PubMed     Text format     Abstract available


  133. WALKER LA, Osman L, Berard JA, Rees LM, et al
    Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project.
    J Neurol Sci. 2016;362:147-52.
    PubMed     Text format     Abstract available


  134. LIU Y, Morgan C, Hornung L, Tyry T, et al
    Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.
    J Neurol Sci. 2016;362:121-6.
    PubMed     Text format     Abstract available


  135. AHMADI M, Emami Aleagha MS, Harirchian MH, Yarani R, et al
    Multiple sclerosis influences on the augmentation of serum Klotho concentration.
    J Neurol Sci. 2016;362:69-72.
    PubMed     Text format     Abstract available


  136. HUDA S, Cavey A, Izat A, Mattison P, et al
    Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.
    J Neurol Sci. 2016;362:66-8.
    PubMed     Text format     Abstract available


    February 2016
  137. FERNANDEZ-MENENDEZ S, Fernandez-Moran M, Fernandez-Vega I, Perez-Alvarez A, et al
    Epstein-Barr virus and multiple sclerosis. From evidence to therapeutic strategies.
    J Neurol Sci. 2016;361:213-9.
    PubMed     Text format     Abstract available


  138. HANNA J, Feinstein A, Morrow SA
    The association of pathological laughing and crying and cognitive impairment in multiple sclerosis.
    J Neurol Sci. 2016;361:200-3.
    PubMed     Text format     Abstract available


  139. RIO J, Ruiz-Pena JL
    Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2016;361:158-67.
    PubMed     Text format    


  140. AGIOVLASITIS S, Sandroff BM, Motl RW
    Step-rate cut-points for physical activity intensity in patients with multiple sclerosis: The effect of disability status.
    J Neurol Sci. 2016;361:95-100.
    PubMed     Text format     Abstract available


  141. FAREZ MF, Correale J
    Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis.
    J Neurol Sci. 2016;361:60-5.
    PubMed     Text format     Abstract available


  142. KALRON A
    Gait variability across the disability spectrum in people with multiple sclerosis.
    J Neurol Sci. 2016;361:1-6.
    PubMed     Text format     Abstract available


    January 2016
  143. SAVIN Z, Lejbkowicz I, Glass-Marmor L, Lavi I, et al
    Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    J Neurol Sci. 2016;360:102-9.
    PubMed     Text format     Abstract available


  144. ALROUGHANI R, Akhtar S, Ahmed SF, Khoury SJ, et al
    JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study.
    J Neurol Sci. 2016;360:61-5.
    PubMed     Text format     Abstract available


  145. ALVAREZ-CERMENO JC, Munoz-Negrete FJ, Costa-Frossard L, de la Maza SS, et al
    Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis.
    J Neurol Sci. 2016;360:41-4.
    PubMed     Text format     Abstract available


  146. DAMASCENO A, Moraes AS, Farias A, Damasceno BP, et al
    A spring to summer shift of pro-inflammatory cytokine production in multiple sclerosis patients.
    J Neurol Sci. 2016;360:37-40.
    PubMed     Text format     Abstract available


  147. MOORE P, Methley A, Pollard C, Mutch K, et al
    Cognitive and psychiatric comorbidities in neuromyelitis optica.
    J Neurol Sci. 2016;360:4-9.
    PubMed     Text format     Abstract available


    December 2015
  148. YOSHII F, Takagi S, Nagata E, Hasegawa Y, et al
    Cognitive impairment of Japanese multiple sclerosis patients: Follow-up study using BRB-N assessment tool.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  149. BEHBEHANI R, Al-Hassan AA, Al-Khars A, Sriraman D, et al
    Retinal nerve fiber layer thickness and neurologic disability in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2015;359.
    PubMed     Text format    


  150. ZAHOOR I, Asimi R, Haq E
    No evidence for a role of Ile587Val polymorphism of EIF2B5 gene in multiple sclerosis in Kashmir Valley of India.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  151. OTERO-ROMERO S, Ramio-Torrenta L, Pericot I, Carmona O, et al
    Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  152. LAMARGUE-HAMEL D, Deloire M, Saubusse A, Ruet A, et al
    Cognitive evaluation by tasks in a virtual reality environment in multiple sclerosis.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  153. GILLI F, Li L, Campbell SJ, Anthony DC, et al
    The effect of B-cell depletion in the Theiler's model of multiple sclerosis.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


    October 2015
  154. CASTELLI L, Stocchi L, Patrignani M, Sellitto G, et al
    We-Measure: Toward a low-cost portable posturography for patients with multiple sclerosis using the commercial Wii balance board.
    J Neurol Sci. 2015 Oct 14. pii: S0022-510X(15)02484.
    PubMed     Text format     Abstract available


    September 2015
  155. KANTELE S, Karinkanta S, Sievanen H
    Effects of long-term whole-body vibration training on mobility in patients with multiple sclerosis: A meta-analysis of randomized controlled trials.
    J Neurol Sci. 2015 Sep 25. pii: S0022-510X(15)02445.
    PubMed     Text format     Abstract available


  156. AYACHE SS, Chalah MA, Al-Ani T, Farhat WH, et al
    Tremor in multiple sclerosis: The intriguing role of the cerebellum.
    J Neurol Sci. 2015 Sep 25. pii: S0022-510X(15)02448.
    PubMed     Text format    


  157. PAU M, Coghe G, Corona F, Marrosu MG, et al
    Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis.
    J Neurol Sci. 2015 Sep 18. pii: S0022-510X(15)02440.
    PubMed     Text format     Abstract available


  158. FARJAM M, Zhang GX, Ciric B, Rostami A, et al
    Emerging immunopharmacological targets in multiple sclerosis.
    J Neurol Sci. 2015 Sep 14. pii: S0022-510X(15)02434.
    PubMed     Text format     Abstract available


  159. DARIJA KT, Tatjana P, Goran T, Nebojsa S, et al
    Sexual dysfunction in multiple sclerosis: A 6-year follow-up study.
    J Neurol Sci. 2015 Sep 10. pii: S0022-510X(15)02111.
    PubMed     Text format     Abstract available


  160. TANIK N, Serin HI, Celikbilek A, Inan LE, et al
    Olfactory bulb and olfactory sulcus depths are associated with disease duration and attack frequency in multiple sclerosis patients.
    J Neurol Sci. 2015 Sep 8. pii: S0022-510X(15)02100.
    PubMed     Text format     Abstract available


  161. PAPATHANASIOU A, Messinis L, Zampakis P, Panagiotakis G, et al
    Thalamic atrophy predicts cognitive impairment in relapsing remitting multiple sclerosis. Effect on instrumental activities of daily living and employment status.
    J Neurol Sci. 2015 Sep 2. pii: S0022-510X(15)02051.
    PubMed     Text format     Abstract available


    August 2015
  162. NOVAKOVA L, Axelsson M, Malmestrom C, Zetterberg H, et al
    Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    J Neurol Sci. 2015 Aug 29. pii: S0022-510X(15)02033.
    PubMed     Text format     Abstract available


  163. KALRON A, Frid L
    The "butterfly diagram": A gait marker for neurological and cerebellar impairment in people with multiple sclerosis.
    J Neurol Sci. 2015 Aug 20. pii: S0022-510X(15)00524.
    PubMed     Text format     Abstract available


  164. AVASARALA J, Zachariah P
    Vitamin D deficiency in multiple sclerosis: Should testing and treatment be based on racial background?
    J Neurol Sci. 2015 Aug 12. pii: S0022-510X(15)00514.
    PubMed     Text format     Abstract available


  165. LOVERA J, Ramos A, Devier D, Garrison V, et al
    Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
    J Neurol Sci. 2015 Aug 7. pii: S0022-510X(15)00499.
    PubMed     Text format     Abstract available


  166. GUZZI G, Costa A, Pigatto P
    Serum NSE and multiple sclerosis.
    J Neurol Sci. 2015 Aug 7. pii: S0022-510X(15)00506.
    PubMed     Text format    


    July 2015
  167. FRNDAK SE, Irwin LN, Kordovski VM, Milleville K, et al
    Negative work events reported online precede job loss in multiple sclerosis.
    J Neurol Sci. 2015 Jul 26. pii: S0022-510X(15)00453.
    PubMed     Text format     Abstract available


  168. LOREFICE L, Murru, Fenu G, Corongiu D, et al
    A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion.
    J Neurol Sci. 2015 Jul 26. pii: S0022-510X(15)00457.
    PubMed     Text format     Abstract available


  169. VOLLMER T, Signorovitch J, Huynh L, Galebach P, et al
    The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis.
    J Neurol Sci. 2015 Jul 13. pii: S0022-510X(15)00435.
    PubMed     Text format     Abstract available


  170. ARRU G, Caggiu E, Leoni S, Mameli G, et al
    Natalizumab modulates the humoral response against HERV-Wenv in a follow-up study of Multiple Sclerosis patients.
    J Neurol Sci. 2015 Jul 8. pii: S0022-510X(15)00428.
    PubMed     Text format     Abstract available


  171. HABEK M, Krbot Skoric M, Crnosija L, Adamec I, et al
    Brainstem dysfunction protects against syncope in multiple sclerosis.
    J Neurol Sci. 2015 Jul 2. pii: S0022-510X(15)00417.
    PubMed     Text format     Abstract available


    June 2015
  172. O'MALLEY PW, Mulla ZD, Nesic O
    Multiple sclerosis and breast cancer.
    J Neurol Sci. 2015 Jun 22. pii: S0022-510X(15)00374.
    PubMed     Text format     Abstract available


  173. PAPAIS-ALVARENGA RM, Pereira FF, Bernardes MS, Papais-Alvarenga M, et al
    Familial forms of multiple sclerosis and neuromyelitis optica at an MS center in Rio de Janeiro State, Brazil.
    J Neurol Sci. 2015 Jun 19. pii: S0022-510X(15)00375.
    PubMed     Text format     Abstract available


  174. SUNDGREN M, Wahlin A, Maurex L, Brismar T, et al
    Event related potential and response time give evidence for a physiological reserve in cognitive functioning in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2015 Jun 16. pii: S0022-510X(15)00366.
    PubMed     Text format     Abstract available


  175. ANDALIB S, Talebi M, Sakhinia E, Farhoudi M, et al
    Lack of association between mitochondrial DNA G15257A and G15812A variations and multiple sclerosis.
    J Neurol Sci. 2015 Jun 12. pii: S0022-510X(15)00363.
    PubMed     Text format     Abstract available


  176. LO AC, Ruiz JA, Koenig CM, Anderson BM, et al
    Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    J Neurol Sci. 2015 Jun 8. pii: S0022-510X(15)00349.
    PubMed     Text format     Abstract available


  177. SUGIYAMA A, Mori M, Masuda H, Uchida T, et al
    Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis.
    J Neurol Sci. 2015 Jun 3. pii: S0022-510X(15)00345.
    PubMed     Text format     Abstract available


    May 2015
  178. ALEXANDER JS, Chervenak R, Weinstock-Guttman B, Tsunoda I, et al
    Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes.
    J Neurol Sci. 2015 May 28. pii: S0022-510X(15)00309.
    PubMed     Text format     Abstract available


  179. MEALY MA, Whetstone A, Orman G, Izbudak I, et al
    Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis.
    J Neurol Sci. 2015 May 17. pii: S0022-510X(15)00295.
    PubMed     Text format     Abstract available


  180. LA PUMA D, Llufriu S, Sepulveda M, Blanco Y, et al
    Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination.
    J Neurol Sci. 2015;352.
    PubMed     Text format    


  181. BRIDOUX A, Creange A, Sangare A, Ayache SS, et al
    Impaired sleep-associated modulation of post-exercise corticomotor depression in multiple sclerosis.
    J Neurol Sci. 2015 May 10. pii: S0022-510X(15)00272.
    PubMed     Text format     Abstract available


  182. MITOLO M, Venneri A, Wilkinson ID, Sharrack B, et al
    Cognitive rehabilitation in multiple sclerosis: A systematic review.
    J Neurol Sci. 2015 May 9. pii: S0022-510X(15)00269.
    PubMed     Text format     Abstract available


  183. ANDALIB S, Talebi M, Sakhinia E, Farhoudi M, et al
    Mitochondrial DNA T4216C and A4917G variations in multiple sclerosis.
    J Neurol Sci. 2015 May 7. pii: S0022-510X(15)00260.
    PubMed     Text format     Abstract available


  184. MOROSO A, Deloire MS, Ruet A, Ouallet JC, et al
    Does cerebrospinal fluid analysis add predictive value to magnetic resonance imaging for long term irreversible disability in patients with early multiple sclerosis?
    J Neurol Sci. 2015 May 2. pii: S0022-510X(15)00254.
    PubMed     Text format     Abstract available


  185. MOTL RW, Hubbard EA, Sreekumar N, Wetter NC, et al
    Pallidal and caudate volumes correlate with walking function in multiple sclerosis.
    J Neurol Sci. 2015 May 1. pii: S0022-510X(15)00251.
    PubMed     Text format     Abstract available


    April 2015
  186. SERGOTT RC, Bennett JL, Rieckmann P, Montalban X, et al
    ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.
    J Neurol Sci. 2015;351.
    PubMed     Text format     Abstract available


    February 2015
  187. MCGEE J, Minagar A
    Co-existence of tumefactive MS and hepatitis C: A need for further screening and new therapeutic challenge.
    J Neurol Sci. 2015;349.
    PubMed     Text format    


  188. PENG JT, Cong HR, Yan R, Kong XY, et al
    Neurological outcome and predictive factors of idiopathic optic neuritis in China.
    J Neurol Sci. 2015;349.
    PubMed     Text format     Abstract available


  189. FRAU J, Cossu D, Coghe G, Lorefice L, et al
    Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients.
    J Neurol Sci. 2015;349.
    PubMed     Text format     Abstract available


    January 2015
  190. AVASARALA JR
    Clinically isolated syndrome--Rethinking the diagnosis.
    J Neurol Sci. 2015;353.
    PubMed     Text format     Abstract available


    October 2014
  191. PULA JH, Kattah JC, Keung B, Wang H, et al
    Longitudinally extensive optic neuritis in neuromyelitis optica spectrum disorder.
    J Neurol Sci. 2014;345.
    PubMed     Text format     Abstract available


  192. KIMURA MC, Doring TM, Rueda FC, Tukamoto G, et al
    In vivo assessment of white matter damage in neuromyelitis optica: a diffusion tensor and diffusion kurtosis MR imaging study.
    J Neurol Sci. 2014;345.
    PubMed     Text format     Abstract available


    September 2014
  193. WILSON L, Loucks A, Bui C, Gipson G, et al
    Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
    J Neurol Sci. 2014;344.
    PubMed     Text format     Abstract available


  194. HELLMANN MA, Lev N, Lotan I, Mosberg-Galili R, et al
    Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
    J Neurol Sci. 2014;344.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: